ReviewMicrobial biotechnology2025
Unlocking the Synthetic Potential of Yarrowia lipolytica: Innovating Gene Expression Tools.
Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High Cell Density Fermentation ofInternational journal of molecular sciences · 2026Article
- Transcriptional regulation: efficient genetic engineering tools for non-conventional yeasts.FEMS yeast research · 2026Review
- Unlocking the Synthetic Potential of Yarrowia lipolytica: Innovating Gene Expression Tools.Microbial biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Yarrowia lipolytica, with its robust lipid metabolism capabilities, efficient secretion system and generally recognised as safe (GRAS) status, has become a highly promising microbial chassis in synthetic biology. However, compared with model microorganisms such as Saccharomyces cerevisiae, the underdevelopment of gene expression tools in Y. lipolytica has become a critical bottleneck, limiting its industrial application. Currently, its core tools face two critical challenges: promoters with limited dynamic regulatory capacity, leading to metabolic flux imbalance; and gene editing systems plagued by low efficiency and poor multiplex compatibility. This opinion article focuses on these two pivotal directions to dissect their technical bottlenecks and propose innovative solutions: constructing dynamic transcriptional regulatory modules through machine learning guided design and synthetic biology approaches and developing orthogonal CRISPR systems and multiplex editing platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.